Green Cross-MSD make explosive growth on ‘Zostavax’

‘Zostavax.’ a MSD’s shingles vaccine co-marketed by Green Cross, has shown an amazing uptrend.

According to the industry concerned, Zostavax has drawn a sharp rising curve with approximately KRW 80 billion sales increased by 25% from the 2015’s KRW 65 billion sales.

Zostavax, the only vaccine which prevents activation of varicella-zoster virus by blocking weakening of immunity, has been co-ma...